A Phase 1 Trial of PT2977, a HIF-2α Inhibitor, in Patients With clear cell renal cell carcinoma (ccRCC).
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2017
At a glance
- Drugs PT 2977 (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 27 Dec 2017 New trial record